Connect with us


AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News

Pascal Soriot isn’t letting the all-consuming R&D and manufacturing work on a Covid-19 vaccine slow down his hunt for AstraZeneca’s next blockbuster cancer drugs. The latest deal with Daiichi Sankyo consists of $1 billion in upfront cash payment spread over 2…



post featured image

A little over a year and a half since its $100M-plus IPO, immunotherapy biotech TCR² Therapeutics $TCRR released the first data from Phase I/II trials for its lead T cell therapy today, with some analysts expressing optimism from the results.
Though the sample size is small, the data from five patients in the Phase I portion showed that none of the five individuals experienced neurotoxicity or on-target, off-tumor toxicities, a primary goal in the trial. Cytokine release syndrome manifested in …

Click here to view the original article.

Continue Reading

You might also like ...

Coronavirus latest: Mall owner Washington Prime files for bankruptcy as rents dry up – Financial Times
Article feature image
First look at Tesla Model S Plaid’s “Auto Shift out of Park” in action – Teslarati
Article feature image
BlackRock’s ETF assets race past $3tn – Financial Times